Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CND-Dox-TF (720456)
- Development stage
- Preclinical
- Lead developer
- University of Miami
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CND-Dox-TF (also known as CDT) is an experimental nanoparticle-drug conjugate designed for the targeted delivery of doxorubicin to malignant cells overexpressing the transferrin receptor 1 (TFR1/CD71). The therapeutic consists of a carbon-nitride dot (CND) scaffold covalently linked to doxorubicin (Dox) and holo-transferrin (TF). The transferrin component acts as a targeting ligand, facilitating clathrin-mediated endocytosis upon binding to TFR1, a receptor frequently upregulated in aggressive cancers such as diffuse large B-cell lymphoma (DLBCL). Once internalized, the doxorubicin payload is released and translocates to the nucleus, where it induces double-stranded DNA breaks and apoptosis. In preclinical models, CDT has demonstrated significantly higher potency than unconjugated doxorubicin and has been evaluated as a component of the 'R-nanoCHOP' regimen (replacing standard doxorubicin in R-CHOP), showing improved overall survival and reduced systemic toxicities, particularly cardiotoxicity and myelosuppression.
- Other names
- CND-DoxCarbon-Nitride Dot-Doxorubicin-Transferrin
02
Targets
DNATFRC (Transferrin Receptor)
Beyond the preview
Go deeper on CND-Dox-TF (720456).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CND-Dox-TF (720456).